Comment from Critical Path Institute

Summary: The Critical Path Institute (C-Path) supports the draft guidance on New Approach Methodologies (NAMs) in drug development, commending the FDA's efforts to modernize regulatory science. They suggest specific enhancements to clarify "fit-for-purpose" principles, recognize data-sharing infrastructure, and better address multi-platform evidence integration and disease heterogeneity.